Oral Phenylephrine Phase-Out debate grows as Sahpra weighs evidence, industry warns on access, and pharmacists call for a gradual transition.
Oral Phenylephrine Phase-Out Puts OTC Brands Under Review
Original Article by Tamar Kahn | Business Day | 21 April 2026
Oral Phenylephrine Phase-Out debate grows as Sahpra weighs evidence, industry warns on access, and pharmacists call for a gradual transition.
More Posts
NHLS Scrambles as Pathology Services Funding Runs Dry
The NHLS is scrambling for new providers after funds for haematology pathology services ran dry, amid an R11.3bn provincial debt
Read more...
Momentum Group Posts Record Earnings
Momentum Group has posted record earnings, with normalised headline earnings up 13% to R7.06bn – beating its R7bn Impact target a year early.
Read more...
Sanlam Writes Down AfroCentric to Nil but Won’t Sell
Sanlam has written its AfroCentric stake down to nil after the Bonitas exit but rules out a sale, betting it can revive the business.
Read more...